| MicroRNA 452 regulates SHC1 expression in human colorectal cancer and colitis. | MicroRNA 452 regulates SHC1 expression in human colorectal cancer and colitis.
Mo JS, Lamichhane S, Yun KJ, Chae SC. | 09/19/2023 |
| YES1 Kinase Mediates the Membrane Removal of Rescued F508del-CFTR in Airway Cells by Promoting MAPK Pathway Activation via SHC1. | YES1 Kinase Mediates the Membrane Removal of Rescued F508del-CFTR in Airway Cells by Promoting MAPK Pathway Activation via SHC1.
Barros P, Matos AM, Matos P, Jordan P., Free PMC Article | 07/5/2023 |
| Mitochondrial Translocation of P66Shc Aggravates Cisplatin-induced AKI by Promoting Ferroptosis. | Mitochondrial Translocation of P66Shc Aggravates Cisplatin-induced AKI by Promoting Ferroptosis.
Yang M, Liu YT, Han YC, Zhang W, Zhang H, Yang S. | 02/13/2023 |
| Dynamics of antioxidant heme oxygenase-1 and pro-oxidant p66Shc in promoting advanced prostate cancer progression. | Dynamics of antioxidant heme oxygenase-1 and pro-oxidant p66Shc in promoting advanced prostate cancer progression.
Miller DR, Ingersoll MA, Chou YW, Kosmacek EA, Oberley-Deegan RE, Lin MF., Free PMC Article | 12/17/2022 |
| The p66Shc Protein Mediates Insulin Resistance and Secretory Dysfunction in Pancreatic beta-Cells Under Lipotoxic Conditions. | The p66Shc Protein Mediates Insulin Resistance and Secretory Dysfunction in Pancreatic β-Cells Under Lipotoxic Conditions.
Biondi G, Marrano N, Dipaola L, Borrelli A, Rella M, D'Oria R, Genchi VA, Caccioppoli C, Porreca I, Cignarelli A, Perrini S, Marchetti P, Vincenti L, Laviola L, Giorgino F, Natalicchio A. | 07/30/2022 |
| The E3 ubiquitin ligase SOCS-7 reverses immunosuppression via Shc1 signaling in hepatocellular carcinoma. | The E3 ubiquitin ligase SOCS-7 reverses immunosuppression via Shc1 signaling in hepatocellular carcinoma.
Huang P, Zhao Z, Chen Y, Yang B, Xia J. | 06/11/2022 |
| Genistein suppresses ox-LDL-elicited oxidative stress and senescence in HUVECs through the SIRT1-p66shc-Foxo3a pathways. | Genistein suppresses ox-LDL-elicited oxidative stress and senescence in HUVECs through the SIRT1-p66shc-Foxo3a pathways.
Zhang H, Pang X, Yu H, Zhou H. | 04/2/2022 |
| The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases. | The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases.
Liang Y, Lei Y, Du M, Liang M, Liu Z, Li X, Gao Y., Free PMC Article | 02/5/2022 |
| Human SHC-transforming protein 1 and its isoforms p66shc: A novel marker for prediabetes. | Human SHC-transforming protein 1 and its isoforms p66shc: A novel marker for prediabetes.
Jelinek HF, Helf C, Khalaf K., Free PMC Article | 02/5/2022 |
| p52Shc regulates the sustainability of ERK activation in a RAF-independent manner. | p52Shc regulates the sustainability of ERK activation in a RAF-independent manner.
Yoshizawa R, Umeki N, Yamamoto A, Okada M, Murata M, Sako Y., Free PMC Article | 01/29/2022 |
| Lower p66Shc promoter methylation in subjects with chronic renal failure. | Lower p66Shc promoter methylation in subjects with chronic renal failure.
Hamdi R, Saadallah-Kallel A, Ferchichi-Trimeche S, Mokdad-Gargouri R, Miled A, Benarba B., Free PMC Article | 11/22/2021 |
| P66Shc Deletion Ameliorates Oxidative Stress and Cardiac Dysfunction in Pressure Overload-Induced Heart Failure. | P66Shc Deletion Ameliorates Oxidative Stress and Cardiac Dysfunction in Pressure Overload-Induced Heart Failure.
Wang Y, Qu H, Liu J. | 09/18/2021 |
| DEPDC1B is a tumor promotor in development of bladder cancer through targeting SHC1. | DEPDC1B is a tumor promotor in development of bladder cancer through targeting SHC1.
Lai CH, Xu K, Zhou J, Wang M, Zhang W, Liu X, Xiong J, Wang T, Wang Q, Wang H, Xu T, Hu H., Free PMC Article | 05/1/2021 |
| Physical activity may drive healthy microvascular ageing via downregulation of p66(Shc). | Physical activity may drive healthy microvascular ageing via downregulation of p66(Shc).
Streese L, Khan AW, Deiseroth A, Hussain S, Suades R, Tiaden A, Kyburz D, Hanssen H, Cosentino F. | 12/26/2020 |
| A SYK/SHC1 pathway regulates the amount of CFTR in the plasma membrane. | A SYK/SHC1 pathway regulates the amount of CFTR in the plasma membrane.
Loureiro CA, Pinto FR, Barros P, Matos P, Jordan P. | 11/28/2020 |
| p66ShcA functions as a contextual promoter of breast cancer metastasis. | p66ShcA functions as a contextual promoter of breast cancer metastasis.
Lewis K, Kiepas A, Hudson J, Senecal J, Ha JR, Voorand E, Annis MG, Sabourin V, Ahn R, La Selva R, Tabariès S, Hsu BE, Siegel MJ, Dankner M, Canedo EC, Lajoie M, Watson IR, Brown CM, Siegel PM, Ursini-Siegel J., Free PMC Article | 10/3/2020 |
| CRIF1 deficiency induced mitophagy via p66shc-regulated ROS in endothelial cells. | CRIF1 deficiency induced mitophagy via p66shc-regulated ROS in endothelial cells.
Piao S, Nagar H, Kim S, Lee I, Choi SJ, Kim T, Jeon BH, Kim CS. | 09/5/2020 |
| PTRF/CAVIN1, regulated by SHC1 through the EGFR pathway, is found in urine exosomes as a potential biomarker of ccRCC. | PTRF/CAVIN1, regulated by SHC1 through the EGFR pathway, is found in urine exosomes as a potential biomarker of ccRCC.
Zhao Y, Wang Y, Zhao E, Tan Y, Geng B, Kang C, Li X. | 08/22/2020 |
| SHC1 was highly expressed in cartilage from osteoarthritis patients. | p66shc siRNA Nanoparticles Ameliorate Chondrocytic Mitochondrial Dysfunction in Osteoarthritis.
Shin HJ, Park H, Shin N, Shin J, Gwon DH, Kwon HH, Yin Y, Hwang JA, Hong J, Heo JY, Kim CS, Joo Y, Kim Y, Kim J, Beom J, Kim DW., Free PMC Article | 08/15/2020 |
| p66Shc has dual role in the development of diabetic retinopathy; its regulation in the early stages of the disease should impede Rac1-ROS production and, in the later stages, prevent mitochondrial damage and initiation of a futile cycle of free radicals. | Adaptor Protein p66Shc: A Link Between Cytosolic and Mitochondrial Dysfunction in the Development of Diabetic Retinopathy.
Mishra M, Duraisamy AJ, Bhattacharjee S, Kowluru RA., Free PMC Article | 07/4/2020 |
| High p66Shc expression in hepatocellular carcinoma (HCC) predicts a worse prognosis for survival. Furthermore, p66Shc may serve as a novel candidate target for HCC therapy. | p66Shc promotes HCC progression in the tumor microenvironment via STAT3 signaling.
Huang P, Feng X, Zhao Z, Yang B, Fang T, Guo M, Xia J. | 07/4/2020 |
| p66Shc (SHC1) protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance. | p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
Miller DR, Ingersoll MA, Chatterjee A, Baker B, Shrishrimal S, Kosmacek EA, Zhu Y, Cheng PW, Oberley-Deegan RE, Lin MF., Free PMC Article | 06/20/2020 |
| In B cell lymphoma cells, reactive oxygen species production promoted p66shc expression, induced DNA damage, and facilitated cell apoptosis. | Oxidative stress induces B lymphocyte DNA damage and apoptosis by upregulating p66shc.
Lang JY, Ma K, Guo JX, Sun H. | 11/9/2019 |
| p66SHC is a novel regulator of autophagy and mitophagy in B cells and mediates coordination of autophagy and apoptosis in B cell survival and differentiation. | The pro-oxidant adaptor p66SHC promotes B cell mitophagy by disrupting mitochondrial integrity and recruiting LC3-II.
Onnis A, Cianfanelli V, Cassioli C, Samardzic D, Pelicci PG, Cecconi F, Baldari CT., Free PMC Article | 10/26/2019 |
| These data demonstrate that metabolic reprogramming is a key component of ShcA signaling and serves an unappreciated yet vital role during breast cancer initiation and progression. These data further unravel a novel interplay between ShcA and PGC-1alpha in the coordination of metabolic reprogramming and demonstrate the sensitivity of breast tumors to drugs targeting oxidative phosphorylation | Interplay between ShcA Signaling and PGC-1α Triggers Targetable Metabolic Vulnerabilities in Breast Cancer.
Im YK, Najyb O, Gravel SP, McGuirk S, Ahn R, Avizonis DZ, Chénard V, Sabourin V, Hudson J, Pawson T, Topisirovic I, Pollak M, St-Pierre J, Ursini-Siegel J. | 09/21/2019 |